Skip to main content
    U

    Uniqure NV (QURE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $21.70
    +0.69 (+3.28%)

    Market Cap: $1.47B

    Last updated: Nov 06, 2026 at 4:27 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(22/40)
    Avg Surprise
    -5.33%

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-1.16
    Range$-1.93 - $-0.74
    11 analysts
    Revenue Consensus
    $6M
    Range$-217740 - $16M
    12 analysts
    Last 12 of 40 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-1.16$-1.93 - $-0.74--11--
    Sep 26
    Reported Nov 4
    		$-0.88$-0.84$-1.05 - $-0.66-4.76%Miss11
    2
    4
    30d
    		+26.1%
    Jun 26
    Reported Jul 29
    		$-1.22$-0.81$-0.88 - $-0.76-50.62%Miss10
    3
    4
    30d
    		-103.3%
    Mar 26
    Reported May 5
    		$-0.73$-0.75$-0.91 - $-0.66+2.67%Beat9
    1
    0
    30d
    		+0.0%
    Dec 25
    Reported Mar 2
    		$-0.47$-0.92$-1.05 - $-0.77+48.31%Beat10
    3
    0
    30d
    		+67.1%
    Sep 25
    Reported Nov 10
    		$-1.19$-0.75$-0.91 - $-0.55-58.67%Miss10
    7
    0
    30d
    		-41.7%
    Jun 25
    Reported Jul 29
    		$-0.60$-0.76$-0.91 - $-0.59+21.05%Beat10
    3
    0
    30d
    		+44.4%
    Mar 25
    Reported May 9
    		$-0.73$-0.93$-1.42 - $-0.57+21.51%Beat10
    3
    0
    30d
    		+42.1%
    Dec 24
    Reported Feb 27
    		$-1.44$-0.52$-1.47 - $1.08-178.82%Miss8
    0
    2
    30d
    		+5.8%
    Sep 24
    Reported Nov 5
    		$-0.84$-0.93$-1.38 - $-0.32+9.68%Beat11
    No revisions (30d)
    		+52.0%
    Jun 24
    Reported Aug 1
    		$-1.08$-1.16$-1.61 - $-0.69+6.90%Beat10
    1
    0
    30d
    		+17.6%
    Mar 24
    Reported May 7
    		$-1.26$-1.16$-1.64 - $-0.90-8.62%Miss13
    No revisions (30d)
    		+14.9%
    Dec 23
    Reported Feb 28
    		$-1.53$-1.46$-1.89 - $-0.61-4.79%Miss13
    No revisions (30d)
    		-1120.0%

    Key Metrics

    Valuation
    P/E Ratio-6.57EV/EBITDAN/A
    Price/FCF-7.86xFCF Yield-12.72%
    Profitability
    Profit Margin0.00%Operating Margin-872.00%
    ROE-157.60%ROIC-57.88%
    Financial Health
    Debt/Equity0.17xInterest Coverage-3.48x
    Current Ratio11.52xQuick Ratio11.52x
    Trading Statistics
    Beta1.13Avg Volume2.04M
    52-Week High$51.7252-Week Low$8.73

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$23.36
    SMA 20$22.76
    SMA 50$31.86
    SMA 200$29.66
    EMA 10$22.88
    EMA 20$24.05
    EMA 50$29.26
    EMA 200$31.10

    MACD

    Line: -2.13Signal: -2.66Hist: 0.53

    ADX

    ADX: 32.9+DI: 17.8-DI: 28.2

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down32.0
    PSAR$26.26

    Bollinger Bands

    Upper Band$25.37
    Lower Band$20.14
    %B Position2299%(Upper)
    Band Width0.30

    RSI (14-Day)

    Neutral
    36.3

    Momentum Oscillators

    Stoch %K18.8
    Stoch %D30.4
    Williams %R-81.4
    ROC (10d)-3.3%
    Momentum-0.73
    CCI (20d)-78.8
    MFI (14d)33.3

    Volatility Measures

    ATR (14d)$1.91(8.8%)
    StdDev (20d)1.31
    Hist Vol77.3%(High)

    Volume Flow

    VWAP$21.58
    OBV32.4M
    AD Line70.1M
    CMF (20d)-0.062

    Volume Metrics

    Avg Vol (20d)2.1M
    Vol Ratio0.6x
    VWMA (20d)$22.59

    Pivot Points

    R3$24.36
    R2$23.52
    R1$22.27
    Pivot Point$21.42
    S1$20.17
    S2$19.33
    S3$18.07

    Advanced Oscillators

    TSI-30.12
    Ultimate Osc46.0
    KST-181.90

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$5.20M$5.84M$3.56M$5.57M$3.70M$5.26M$1.57M$5.22M$2.29M$11.13M$8.48M$6.69M
    Cost of Revenue$236,000$350,000$219,000$435,000$398,000$656,000$197,000$619,000$264,000$234,000$150,000$65,000
    Gross Profit$4.96M$5.49M$3.34M$5.13M$3.30M$4.61M$1.37M$4.60M$2.02M$10.89M$8.34M$6.62M
    Operating Expenses$57.94M$57.69M$49.06M$56.25M$54.34M$48.47M$40.70M$50.43M$42.25M$54.90M$62.56M$68.37M
    R&D$35.52M$33.96M$29.18M$34.78M$34.37M$35.38M$36.14M$38.84M$30.59M$33.66M$40.69M$42.62M
    SG&A$24.11M$25.33M$21.52M$23.46M$21.48M$15.69M$12.87M$13.57M$13.49M$16.00M$14.17M$18.50M
    Operating Income$-52,980,000$-52,203,000$-45,720,000$-51,118,000$-51,035,000$-43,865,000$-39,331,000$-45,828,000$-40,228,000$-44,010,000$-54,228,000$-61,748,000
    Interest Income$8.11M$5.05M$5.23M$5.81M$3.50M$3.52M$4.13M$4.24M$4.87M$5.80M$6.51M$7.17M
    Interest Expense$14.58M$14.37M$14.03M$14.57M$16.72M$15.59M$15.11M$14.88M$16.61M$16.16M$16.10M$15.71M
    Income Before Tax$-60,541,000$-79,218,000$-53,047,000$-41,002,000$-71,903,000$-37,294,000$-43,141,000$-72,405,000$-44,409,000$-55,351,000$-64,962,000$-70,172,000
    Income Tax Expense$676,000$1.84M$488,000$-3,916,000$8.63M$425,000$496,000$856,000$-31,000$948,000$656,000$3.03M
    Net Income$-61,217,000$-81,059,000$-53,535,000$-37,086,000$-80,529,000$-37,719,000$-43,637,000$-73,261,000$-44,378,000$-56,299,000$-65,618,000$-73,206,000
    EBITDA$-54,321,000$-68,568,000$-45,624,000$-33,644,000$-56,981,000$-23,643,000$-29,749,000$-59,838,000$-31,478,000$-45,306,000$-56,439,000$-61,830,000
    EBIT$-54,079,000$-69,903,000$-44,245,000$-32,242,000$-58,685,000$-25,227,000$-32,159,000$-61,765,000$-32,664,000$-44,999,000$-55,373,000$-61,630,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about QURE

    News

    uniQure Q3 2026 Earnings Call Transcript

    uniQure announced the FDA's priority review acceptance of its BLA for AMT-130, a Huntington's disease treatment, with a PDUFA date of May 1...

    Benzinga•11/4/26•Neutral

    Revenue rose to $14.6M at uniQure (QURE), but its nine-month loss widened.

    uniQure N.V. reported a widened net loss of $195.8 million for the nine months ended September 30, 2026, compared to $161.9 million in the same period of 2025...

    Stock Titan•11/4/26•Somewhat-Bearish

    uniQure Wins FDA Priority Review for Huntington’s Gene Therapy BLA

    uniQure announced that the FDA has granted Priority Review for its Huntington’s disease gene therapy application (ifezuntirgene inilparvovec), setting a target decision date of May 1, 2027. The application...

    TradingView•11/2/26•Bullish

    uniQure announces FDA acceptance, priority review for ifezuntirgene inilparvovec

    uniQure announced that the FDA has accepted its Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington’s disease...

    TipRanks•11/2/26•Bullish

    FDA grants uniQure’s Huntington’s gene therapy Priority Review on small, externally controlled dataset

    The US FDA has accepted uniQure's investigational Huntington's disease gene therapy, ifezuntirgene inilparvovec (AMT-130), for Priority Review, setting a PDUFA target action date of May 1, 2027. The therapy...

    AllSci•11/2/26•Bullish

    QURE Valuation and Fair Value

    P/E
    -6.6x
    Forward P/E
    5.0x
    P/FCF
    -7.9x
    PEG
    0.0x
    P/B
    5.1x
    See GNG's fair value

    QURE Profitability: Margins, ROIC and FCF

    Gross margin
    93.9%
    Operating margin
    -872.0%
    Net margin
    0.0%
    ROIC
    -57.9%
    ROE
    -157.6%
    FCF margin
    -956.8%
    FCF yield
    -12.7%

    QURE Competitors

    CompanyTicker
    Tyra Biosciences IncTYRA
    Nuvation Bio IncNUVB
    Precigen IncPGEN
    Immunocore Holdings LtdIMCR
    Supernus Pharmaceuticals, Inc.SUPN
    Pacira BioSciences, Inc.PCRX
    RAPT Therapeutics IncRAPT
    U.S. Physical Therapy, Inc.USPH

    Sector: Healthcare

    QURE Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    2
    Buy
    9
    Hold
    1
    Sell
    0
    Strong Sell
    0

    QURE Bull Case vs Bear Case

    Bull case

    • QURE grew quarterly revenue 11.0% year over year.
    • 91.7% of QURE's analyst ratings are Buy or Strong Buy.

    QURE Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -24.9%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-1.16

    QURE Earnings Call

    The latest QURE earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    QURE ETF Holders

    GNG tracks 6 ETFs that hold QURE. The largest weights:

    1. State Street SPDR S&P Biotech ETF (XBI), 0.49% of the fund
    2. iShares Biotechnology ETF (IBB), 0.11% of the fund
    3. Vanguard Extended Market Index Fund ETF Shares (VXF), 0.04% of the fund
    4. Vanguard Health Care Index Fund ETF Shares (VHT), 0.02% of the fund
    5. iShares Core S&P Total U.S. Stock Market ETF (ITOT), <0.01% of the fund
    Open the ETF Stock Exposure tool for QURE

    See insider activity

    Frequently Asked Questions About QURE

    Does QURE pay dividends?

    Uniqure NV (QURE) does not currently pay a regular dividend.

    What is QURE's market cap?

    Uniqure NV (QURE) has a market capitalization of $1.47B with a current stock price of $21.70.

    Related stocks

    Sector: Healthcare

    All stocks starting with Q

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In